<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01632306</url>
  </required_header>
  <id_info>
    <org_study_id>14453</org_study_id>
    <secondary_id>I2H-MC-JWYD</secondary_id>
    <nct_id>NCT01632306</nct_id>
    <nct_alias>NCT01671202</nct_alias>
  </id_info>
  <brief_title>A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer</brief_title>
  <official_title>Phase I/II Study of LY2090314 and Chemotherapy in Metastatic Pancreatic Cancer Patients With Metastases Amenable to Biopsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose of this phase I/II study is to test how well LY2090314 works in combination with
      different chemotherapies in treating participants with metastatic pancreatic cancer.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study has been terminated due to slow enrollment.
  </why_stopped>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline to 4 Hours Post-Treatment on Day 0 in Glycogen Synthase Phosphorylation</measure>
    <time_frame>Baseline, 4 Hours Post-Treatment on Day 0</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Baseline to Date of Death to any cause up to 2 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 Months Survival</measure>
    <time_frame>Baseline to Date of Death to any cause up to 6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Baseline to Disease Progression up to 2 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Confirmed Tumor Response</measure>
    <time_frame>Up to 8 Months from Baseline</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>LY2090314 + Gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY2090314 given intravenously (IV) on days 1 (at cycle 1 LY2090314 given on day 0 instead of day 1), 8 and 15 in 28 day cycle in combination with 1000 milligram/square meter (mg/m^2) gemcitabine given IV on days 1, 8 and 15. Cohort closed to new enrollment per protocol addendum.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2090314 + FOLFOX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY2090314 given IV on days 1 (at cycle 1 LY2090314 given on day 0 instead of day 1), and 15 in 28 day cycle in combination with FOLFOX (leucovorin + 5-fluorouracil + oxaliplatin) given IV, on days 1 and 15 in 28 day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2090314 + Gemcitabine + Nab-paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY2090314 given IV on days 1 (at cycle 1 LY2090314 given on day 0 instead of day 1), 8 and 15 in 28 day cycle in combination with 1000 mg/m^2 gemcitabine + 125 mg/m^2 nab-paclitaxel given IV on days 1, 8 and 15 in 28-day cycle. New cohort opened per protocol amendment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2090314</intervention_name>
    <description>LY2090314 administered IV</description>
    <arm_group_label>LY2090314 + Gemcitabine</arm_group_label>
    <arm_group_label>LY2090314 + FOLFOX</arm_group_label>
    <arm_group_label>LY2090314 + Gemcitabine + Nab-paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOX</intervention_name>
    <description>FOLFOX administered IV</description>
    <arm_group_label>LY2090314 + FOLFOX</arm_group_label>
    <other_name>FOLFOX (leucovorin + 5-fluorouracil + oxaliplatin)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine administered IV</description>
    <arm_group_label>LY2090314 + Gemcitabine</arm_group_label>
    <arm_group_label>LY2090314 + Gemcitabine + Nab-paclitaxel</arm_group_label>
    <other_name>Gemzar</other_name>
    <other_name>LY188011</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel</intervention_name>
    <description>Nab-paclitaxel administered IV</description>
    <arm_group_label>LY2090314 + Gemcitabine + Nab-paclitaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Metastatic pancreatic cancer with metastases amenable to biopsy

          -  Willingness to provide tissue and blood samples for research purposes

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1

        Exclusion Criteria:

          -  History of islet cell, acinar cell, or cystadenocarcinomas

          -  Prior cytotoxic chemotherapy for metastatic disease, except prior gemcitabine or
             FOLFIRINOX (5FU + leucovorin + irinotecan + oxaliplatin)

          -  Radiation therapy, immunotherapy or biologic therapy &lt;28 days prior to study entry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic of Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 28, 2012</study_first_submitted>
  <study_first_submitted_qc>June 28, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2012</study_first_posted>
  <disposition_first_submitted>March 28, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>March 28, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 29, 2016</disposition_first_posted>
  <last_update_submitted>March 28, 2016</last_update_submitted>
  <last_update_submitted_qc>March 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

